Soleno Therapeutics (SLNO) announced the appointment of biopharmaceutical finance veteran Mark Hahn as an independent director to its Board of Directors and a member of its Audit Committee. With the addition of Hahn, the Soleno Board increases to seven seats. Prior to joining the Soleno Board, Hahn served as Chief Financial Officer of Verona Pharma (VRNA)
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- 3 Best Stocks to Buy Now, 10/7/2025, According to Top Analysts
- Soleno Therapeutics initiated with a Buy at Goldman Sachs
- Buy Rating for Soleno Therapeutics: Strong Market Potential and Growth Opportunities with Vykat XR
- Positive Outlook for Soleno Therapeutics Amid Competitive Setback and Strong VYKAT XR Performance
- Video: Soleno Therapeutics stock rallies on competitor’s failed trial